Ingenuity Expands Scope of Licensing Agreement with Sanofi-Aventis
News Mar 08, 2006
Ingenuity Pathways Analysis is a web-delivered software application that is designed to enable researchers to model, analyze and understand the complex biological systems at the core of life science research.
Ingenuity Pathways Analysis supports analysis of high throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.
"Sanofi-aventis was one of the earliest adopters of Ingenuity technology and we are very pleased that we have been able to expand our relationship with this terrific team year after year," stated Peter DiLaura, Vice President, Sales and Customer Support.
"The Ingenuity product line enables IPA users to understand complex biology within their research, in addition to supporting the Bioinformatics team to further develop robust and proprietary computational solutions."
Ingenuity Pathways Analysis is available as a web-delivered, hosted, or deployed solution. Fully functional complimentary trials are available online.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.